2,308 Shares in Revolution Medicines, Inc. $RVMD Purchased by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp bought a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 2,308 shares of the company’s stock, valued at approximately $432,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Contravisory Investment Management Inc. bought a new stake in shares of Revolution Medicines in the second quarter worth approximately $32,000. Global Retirement Partners LLC raised its holdings in shares of Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after purchasing an additional 361 shares during the last quarter. Torren Management LLC bought a new position in Revolution Medicines during the fourth quarter valued at approximately $33,000. Johnson Financial Group Inc. bought a new position in Revolution Medicines during the second quarter valued at approximately $37,000. Finally, Arax Advisory Partners bought a new position in Revolution Medicines during the fourth quarter valued at approximately $38,000. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Price Performance

Shares of NASDAQ:RVMD opened at $221.15 on Friday. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $47.40 billion, a PE ratio of -25.07 and a beta of 1.39. The firm’s 50 day moving average price is $192.43 and its 200-day moving average price is $148.17. Revolution Medicines, Inc. has a twelve month low of $37.56 and a twelve month high of $224.31.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the prior year, the company posted ($1.31) EPS. Equities research analysts expect that Revolution Medicines, Inc. will post -8.82 EPS for the current year.

Key Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Sanford C. Bernstein lifted their target price on shares of Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a research report on Friday, August 21st. Wedbush increased their price target on Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday. Royal Bank Of Canada raised their price target on Revolution Medicines from $203.00 to $251.00 and gave the stock an “outperform” rating in a research note on Thursday. Truist Financial raised their price target on Revolution Medicines from $231.00 to $239.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Revolution Medicines has a consensus rating of “Moderate Buy” and a consensus target price of $193.28.

Insider Buying and Selling at Revolution Medicines

In related news, CFO Jack Anders sold 20,000 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the transaction, the chief financial officer directly owned 123,269 shares of the company’s stock, valued at approximately $20,749,870.77. This trade represents a 13.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Sushil Patel sold 5,580 shares of Revolution Medicines stock in a transaction on Monday, June 29th. The shares were sold at an average price of $187.99, for a total value of $1,048,984.20. Following the transaction, the director owned 21,656 shares in the company, valued at $4,071,111.44. This trade represents a 20.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 212,497 shares of company stock worth $38,206,486. Insiders own 7.60% of the company’s stock.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.